YRDC and lung adenocarcinoma: YRDC was highly expressed in 12 of 23 available solid tumor tissues (p < 0.05, Wilcoxon test, Figure 2A), including breast invasive carcinoma (BRCA), cholangiocarcinoma (CHOL), colon cancer (COAD), esophageal carcinoma (ESCA), head and neck squamous cell carcinoma (HNSC), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), prostate adenocarcinoma (PRAD), stomach adenocarcinoma (STAD), and uterine corpus endometrial carcinoma (UCEC).